SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and patients, today reported data from its pivotal ...

Staying true to its pledge to crack down on potentially anticompetitive megamergers in the healthcare industry, the U.S. Federal Trade Commission has ordered Medtronic and Intersect ENT to adjust the ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported ...

It may have taken an order from the Federal Trade Commission to get there—and Medtronic may be getting less bang for its buck than initially expected—but the medtech giant’s acquisition of Intersect ...

Medtronic's proposed acquisition of Intersect ENT raised some eyebrows at the Federal Trade Commission. The FTC ordered Medtronic to divest Intersect's Fiagon business within 10 days of the ...

Intersect ENT has announced it has received FDA approval of the company’s second steroid-releasing product, according to a news release (pdf). The PROPEL mini is designed for localized drug delivery ...

Intersect ENT Inc. XENT reported third-quarter 2021 adjusted loss per share of 48 cents, wider than the Zacks Consensus Estimate of a loss of 42 cents. The figure was also wider than the year-ago ...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like ...

A month has gone by since the last earnings report for Intersect ENT (XENT). Shares have lost about 18.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

A month has gone by since the last earnings report for Intersect ENT (XENT). Shares have added about 17.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...